Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 530 of 5804
-
Spinal zaps may reboot arm movement after paralysis or stroke
Disease control Recruiting nowTranscutaneous electrical stimulation (tcES) of the spinal cord has shown great promise in restoring upper extremity function after spinal cord injury (SCI). More recently, the use of invasive, epidural electrical stimulation of the spinal cord has also demonstrated promise in re…
Phase: PHASE2, PHASE3 • Sponsor: University of Alberta • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Radioactive 'Bullets' aim to stop ovarian cancer spread in new trial
Disease control Recruiting nowThis is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian can…
Phase: PHASE2 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New pill aims to slash severe hypoglycemia in type 1 diabetes
Disease control Recruiting nowThis is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Phase: PHASE3 • Sponsor: vTv Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Heart showdown: stents vs. bypass surgery in diabetes patients
Disease control Recruiting nowThe objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).
Phase: NA • Sponsor: Duk-Woo Park, MD • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New shot could tame tough eczema in large trial
Disease control OngoingThis trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with atopic dermatitis.
Phase: PHASE3 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 15:54 UTC
-
New hope for eczema sufferers: drug switch trial launches
Disease control Recruiting nowAtopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma
Disease control Recruiting nowThis study aims to provide a basis for further clinical development of YKST02. YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease.
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New triple therapy shows promise in shrinking advanced stomach tumors before surgery
Disease control Recruiting nowThis Phase II clinical study is a prospective, open-label, single-arm trial designed to evaluate the efficacy and safety of combining anti-PD-1 therapy (Serplulimab) with thymalfasin and the SOX chemotherapy regimen as a neoadjuvant treatment for patients with clinical stage III …
Phase: PHASE2 • Sponsor: Zekuan Xu • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Single shot could lift postpartum depression, early trial hints
Symptom relief CompletedThe purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.
Phase: PHASE2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to stop aggressive lymphoma relapse
Disease control Recruiting nowThis study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whic…
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to fight lung cancer without chemo
Disease control OngoingThe goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic non-small cell lung cancer (NSCLC) as a first-line treatment.
Phase: PHASE2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Smart algorithm picks better fluids for sepsis, may save lives
Disease control CompletedFluids are one of the most common treatments given to patients in the hospital. Fluids are especially important in treating patients with sepsis. Multiple clinical studies have compared the two main types of fluids used in sepsis (normal saline and balanced crystalloids). However…
Phase: NA • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug DD01 shows promise for fatty liver in early trial
Disease control CompletedThis is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Phase: PHASE2 • Sponsor: Neuraly, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for recurrent endometrial cancer: drug combo shows promise
Disease control Recruiting nowThe goal of this clinical trial is to evaluate the efficacy and safety of cadonilimab in combination with paclitaxel, cisplatin, and radiation therapy for the treatment of locally recurrent and oligometastatic endometrial carcinoma. The main questions it aims to answer are: 1. D…
Phase: PHASE2 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New immunotherapy combo may let older colorectal cancer patients skip surgery
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater …
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Donor immune cells take on autoimmune kidney disease in early trial
Disease control Recruiting nowThis is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
Phase: PHASE1, PHASE2 • Sponsor: Nkarta, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy targets tough lymphoma in early trial
Disease control Recruiting nowThis phase Ib/II clinical trial tests the safety, side effects, and effectiveness of mosunetuzumab with chemotherapy for the treatment of patients with untreated, c-Myc rearrangement positive, high grade B cell lymphoma or diffuse large B cell lymphoma. A monoclonal antibody is a…
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Gene therapy breakthrough targets severe epilepsy in first human trial
Disease control Recruiting nowThe main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
Phase: PHASE1, PHASE2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Chemo, immunotherapy, and targeted radiation join forces against bile duct cancer
Disease control Recruiting nowThe purpose of this research is to see if combining gemcitabine, cisplatin and Durvalumab chemotherapy treatments with a direct tumor therapy called Yittrium-90, will work better together to shrink the tumor and control cancer.
Phase: PHASE2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New smart drug targets Hard-to-Treat cancers
Disease control Recruiting nowThe purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antib…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC